Dr. Timothy Joseph O'leary, MD, PHD Pathology - Molecular Genetic Pathology Medicare: Not Enrolled in Medicare Practice Location: 4755 Camp Roosevelt Drive, Chesapeake Beach, MD 20732 Phone: 240-460-0271 |
News Archive
Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.
Maxygen, Inc., a biopharmaceutical company focused on the development of improved versions of protein drugs, today announced the final results of its modified "Dutch Auction" tender offer, which expired at 5:00 p.m., New York City time, on December 23, 2009.
Seven of ten persons with obesity suffer from the serious metabolic complications. Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden have now been entrusted with the task of leading an international research project to develop methods for identifying which individuals are in the risk zone.
Hana Biosciences Inc.,, today announced complete data from its pivotal, Phase 2 RALLY clinical trial for Marqibo® (vincristine sulfate liposome injection) for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Results from the RALLY trial demonstrated compelling evidence of single-agent, anti-leukemic activity in an advanced, heavily pre-treated, adult ALL population.
› Verified 2 days ago